AMGN vs REGN
AMGN and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $197.63B | — |
| P/E (TTM) | 25.5 | 16.5 |
| P/B | 21.50 | — |
| P/S | 5.4x | — |
| Dividend yield | 2.59% | — |
| Revenue | $37.22B(TTM) | $14.92B(TTM) |
| Revenue growth (YoY) | 10.0% | 1.0% |
| Net income | $7.80B(TTM) | $4.42B(TTM) |
| Earnings growth (YoY) | 88.5% | 2.1% |
| EPS, diluted | $14.37(TTM) | $40.96(TTM) |
| EBIT margin | 24.7% | 24.9% |
| ROE | 83.9% | 14.3% |
| ROIC | 15.3% | 9.6% |
| 1y total return | +26.0% | +23.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: AMGN frente a REGN
| Métrica | AMGN | REGN |
|---|---|---|
| Valor final | $34.7K | $18.6K |
| Retorno total | +246.9% | +85.8% |
| CAGR | +12.8% | +6.2% |
| Volatilidad | 24.7% | 32.4% |
| Sharpe | 0.46 | 0.23 |
| Sortino | 0.67 | 0.33 |
| Caída máxima | -24.9% | -59.7% |
Basado en 2600 días de negociación comunes, 2016-03-15 → 2026-07-17 · tasa libre de riesgo 3.85% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)